GSK Receives Approval for Trelegy Ellipta as First Triple Therapy for Asthma in China
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Source: seekingalpha
- New Indication Approved: GSK announced that its Trelegy Ellipta has received approval from China's National Medical Products Administration for treating adult asthma, marking an expansion of its indication from chronic obstructive pulmonary disease, thereby broadening its market potential.
- Unique Triple Therapy: This approval makes Trelegy Ellipta the first and only single-inhaler triple therapy approved for the maintenance treatment of both chronic obstructive pulmonary disease and asthma in China, enhancing the product's competitive edge in the market.
- Clinical Research Support: The approval is based on GSK's CAPTAIN study, which demonstrated that in patients uncontrolled on inhaled corticosteroids/long-acting beta agonists (ICS/LABA), the additional bronchodilation provided by FF/UMEC/VI significantly improved lung function, thereby enhancing treatment efficacy.
- Broad Market Prospects: With the increasing number of asthma patients, GSK's new indication not only addresses the needs of inadequately treated patients but also has the potential to increase the company's market share in the respiratory drug sector by offering more effective treatment options.
Analyst Views on GSK
Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 38.72 USD with a low forecast of 20.15 USD and a high forecast of 55.60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
1 Buy
2 Hold
3 Sell
Moderate Sell
Current: 50.800
Low
20.15
Averages
38.72
High
55.60
Current: 50.800
Low
20.15
Averages
38.72
High
55.60
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
